Thrombin receptor antagonists for the treatment of atherothrombosis: Therapeutic potential of vorapaxar and E-5555

Drugs

Volumn 70, Issue 14, 2010, Pages 1771-1783

  Leonardi, Sergio ^a,b   Tricoci, Pierluigi ^a,c   Becker, Richard C ^a,c  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aspirin, therapeutic use; Atherosclerosis; Cangrelor, therapeutic use; Clopidogrel, therapeutic use; E 5555, therapeutic use; PAR 1 receptor antagonists, therapeutic use; Prasugrel, therapeutic use; Research and development; Thrombin receptor antagonists, therapeutic use; Ticagrelor, therapeutic use; Vorapaxar, therapeutic use.

Indexed keywords

(1 (3 TERT BUTYL 4 METHOXY 5 MORPHOLINOPHENYL) 2 (5,6 DIETHOXY FLURO 1 IMINO 1,3 DIHYDRO 2H ISOINDOL 2YL) ETHANONE HYDROBROMIDE; 3A,4,4A,5,6,7,8,8A,9,9A DECAHYDRO N [4 [2 [5 (3 FLUOROPHENYL) 2 PYRIDYL]VINYL] 3 METHYL 1 OXO 3H BENZO[F]ISOBENZOFURAN 7 YL]CARBAMIC ACID ETHYL ESTER; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; CD31 ANTIGEN; CD40 ANTIGEN; CINNAMOYLPYRIDINE; CLOPIDOGREL; CYTOCHROME P450 3A4; E 5555; F 16357; F 16618; G PROTEIN COUPLED RECEPTOR; KETOCONAZOLE; LIGAND; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PADGEM PROTEIN; PLACEBO; PROTEINASE ACTIVATED RECEPTOR 1; PURINERGIC P2Y12 RECEPTOR; RIFAMPICIN; THIENOPYRIDINE DERIVATIVE; THROMBIN; THROMBIN RECEPTOR ANTAGONIST; THROMBOSPONDIN; THROMBOXANE A2; UNCLASSIFIED DRUG; VITRONECTIN; VORAPAXAR;

ANGIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; ARTERIOVENOUS SHUNT; ATHEROTHROMBOSIS; BLEEDING; BLOOD SAMPLING; BRAIN VASOSPASM; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; EXTRACORPOREAL CIRCULATION; FOLLOW UP; GLYCOSYLATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; IC 50; LIGAND BINDING; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MOLECULAR BEACON; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; REVIEW; SINGLE DRUG DOSE; ST SEGMENT ELEVATION; STROKE; SUBARACHNOID HEMORRHAGE; TABLET; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; URINARY EXCRETION;

ATHEROSCLEROSIS; HUMANS; IMINES; LACTONES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTORS, THROMBIN; THROMBOSIS;

EID: 77956600237     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11538060-000000000-00000     Document Type: Review

References (60)

1. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 2006; 99: 1293-1304
2. Roth GJSN, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci\USA 1975; 72: 3073-3076
3. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502
4. Wiviott SD, Braunwald E, McCabe CH, et al., TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015
5. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057
6. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361: 2330-2341
7. Mann KG. Thrombin formation. Chest 2003; 124: 4S-10S
8. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-264
9. Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci\USA 1999; 96: 11023-11027
10. Chackalamannil S. Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects. J Med Chem 2006; 49: 5389-5403
11. Gurbel PA, Tantry US. Combination antithrombotic ther-apies. Circulation 2010; 121: 569-583
12. Schomig A, Neumann F-J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-1089
13. Leon MBBD, Popma JJ, Gordon PC, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting: stent anticoagulation restenosis study investigators. N Engl J Med 1998; 339: 1665-1671
14. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-857
15. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362
16. Eikelboom JW, Weitz JI, Budaj A, et al. Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. Eur Heart J 2002; 23: 1771-1779
17. Cattaneo M, Zighetti ML, Lombardi R, et al. Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding. Proc Natl Acad Sci\USA 2003; 100: 1978-1983
18. Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of athero-thrombotic events. N Engl J Med 2006; 354: 1706-1717
19. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing nonurgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009; 373: 919-928
20. Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 2008; 51: 3061-3064
21. Serebruany VL, Kogushi M, Dastros-Pitei D, et al. The in-vitro effects of E5555 a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb Haemost 2009; 102: 111-119
22. Vu TK, Hung DT, Wheaton VI, et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-1068
23. Soto AG, Trejo J. N-Linked glycosylation of protease-activated receptor-1 second extracellular loop. J Biol Chem 2010; 285: 18781-18793
24. Gandhi PS, Chen Z, Di Cera E. Crystal structure of thrombin bound to the uncleaved extracellular fragment of PAR1. J Biol Chem 2010; 285: 15393-15398
25. Marino F, Pelc LA, Vogt A, et al. Engineering thrombin for selective specificity toward protein C and PAR1. J Biol Chem 2010; 285: 19145-19152
26. Kahn ML, Zheng Y-W, Huang W, et al. A dual thrombin receptor system for platelet activation. Nature 1998; 394: 690-694
27. Harker LA, Hanson SR, Runge MS. Thrombin hypothesis of thrombus generation and vascular lesion formation. Am J Cardiol 1995; 75: 12B-7B
28. Xu W-f, Andersen H, Whitmore TE, et al. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci\USA 1998; 95: 6642-6646
29. Hirano K. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2007; 27: 27-36
30. London FS, Marcinkiewicz M, Walsh PN. PAR-1-stimulated factor IXa binding to a small platelet sub-population requires a pronounced and sustained increase of cytoplasmic calcium. Biochemistry 2006; 45: 7289-7298
31. Keuren JFW, Wielders SJH, Ulrichts H, et al. Synergistic effect of thrombin on collagen-induced platelet procoagu-lant activity is mediated through protease-activated re-ceptor-1. Arterioscler Thromb Vasc Biol 2005; 25: 1499-1505
32. Riewald M, Kravchenko VV, Petrovan RJ, et al. Gene in-duction by coagulation factor Xa is mediated by activation of protease-activated receptor 1. Blood 2001; 97: 3109-3116
33. Schuepbach RA, Riewald M. Coagulation factor Xa cleaves protease-activated receptor-1 and mediates signaling dependent on binding to the endothelial protein C receptor. J Thromb Haemost 2010; 8: 379-388
34. Lova P, Campus F, Lombardi R, et al. Contribution of protease-activated receptors 1 and 4 and glycoprotein Ib-IX-V in the G(i)-independent activation of platelet Rap1B by thrombin. J Biol Chem 2004; 279: 25299-25306
35. Dubois C, Steiner B, Meyer Reigner SC. Contribution of PAR-1, PAR-4 and GPIbalpha in intracellular signaling leading to the cleavage of the beta3 cytoplasmic domain during thrombin-induced platelet aggregation. Thromb Haemost 2004; 91: 733-742
36. Swift S, Xu J, Trivedi V, et al. A Novel Protease-activated receptor-1 interactor, bicaudal D1, regulates G protein signaling and internalization. J Biol Chem 2010; 285: 11402-11410
37. Andrade-Gordon P, Maryanoff BE, Derian CK, et al. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci\USA 1999; 96: 12257-12262
38. Chackalamannil SDR, Asberom T, Doller D, et al. A highly efficient total synthesis of (+)-himbacine. J Am Chem Soc 1996; 118: 9812-9813
39. Doller DCS, Czarniecki M, McQuade R, et al. Design, synthesis, and structure-activity relationship studies of himbacine derived muscarinic receptor antagonists. Bioorg Med Chem Lett 1999; 9: 901-906
40. Pharmacology of a selective, orally active thrombin receptor antagonist, SCH 530348. Report no. 46293. Kenilworth (NJ): Schering-Plough Research Institute, 2004
41. Chintala MVS, Kurowski S, Sabin C, et al. SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in cynomolgus monkeys [abstract no. P579]. Atheroscler Thromb Vasc Biol 2008; 28: e32-149
42. Kosoglou TRL, Tiessen R, Fales RR, et al. Trap-induced platelet aggregation following single and multiple rising oral doses of SCH 530348, a novel thrombin receptor antagonist, in healthy volunteers [abstract no. PI-40]. Clin Pharmacol Ther 2009; 85 Suppl. 1: 40
43. Kosoglou TRL, Kasserra C, Young S, et al. Optimizing dose of the novel thrombin receptor antagonist SCH 530348 based on pharmacodynamics and pharmacokinetics in healthy subjects [abstract no. PII-42]. Clin Pharmacol Ther 2008; 83 Suppl. 1: S55
44. SCH 530348: rising-multiple-dose safety and tolerance study of SCH 530348 in healthy volunteers [study report for protocol P03450]. Document ID 2926091. Kenilworth (NJ): Schering-Plough Research Institute, 2006
45. Jennings LKEA, Becker RC, Reyderman L, et al. Thrombin receptor antagonist (TRA; SCH530348) is a selective, potent inhibitor of PAR1 activity with predictable pharm-acokinetics [abstract no. 3010]. Circulation 2007; 116: 674
46. Chintala M, Kurowski S, Zhai Y, et al. SCH 530348 Is a novel oral antiplatelet agent selective for protease-activated receptor-1 (PAR-1) receptor subtype without partial agonist activity. FASEB J 2009; 23: 757.6
47. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3: 1800-1814
48. Sambrano GR, Weiss EJ, Zheng Y-W, et al. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001; 413: 74-78
49. Hamilton JR, Cornelissen I, Coughlin SR. Impaired hemo-stasis and protection against thrombosis in protease-acti-vated receptor 4-deficient mice is due to lack of thrombin signaling in platelets. J Thromb Haemost 2004; 2: 1429-1435
50. SCH 530348: influence of chronic renal disease and hemo-dialysis on the single-dose pharmacokinetics and pharmacodynamics of SCH 530348 [study report for protocol P03464]. Document ID 3303095. Kenilworth(NJ): Schering-Plough Research Institute, 2005
51. Reyderman L, Kosoglu T, Tseng J, et al. The effect of food and antiacid on pharmacokinetics (PK) of SCH 530348 in healthy subjects [poster no. PI-42]. Clin Pharmacol Ther 2009; 85 Suppl. 1: S21
52. Goto SYT, Ikeda Y, Kato K, et al. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH 530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb 2010; 17: 156-164
53. Matsuoka T, Kogushi M, Kawata T, et al. Inhibitory effect of E5555, an orally active thrombin receptor antagonist, on intimal hyperplasia following balloon injury [abstract]. J Am Coll Cardiol 2004; 43: 68A
54. Kogushi M, Kobayashi H, Matsuoka T, et al. Antithrom-botic and bleeding time effects of E5555, an orally active protease-activated receptor-1 antagonist, in guinea pigs [abstract]. Circulation 2003; 108 Suppl. IV: 280
55. Kogushi M, Yokohama H, Kitamura S, et al. Effects of E5555, a protease-activated receptor-1 antagonist, on the inflammatory markers in vitro [abstract no. PM-059]. XXIst Congress of the International Society on Thrombosis and Haemostasis; 2007 Jul 6-12; Geneva
56. Kai Y, Hirano K, Maeda Y, et al. Prevention of the hyper-contractile response to thrombin by proteinase-activated receptor-1 antagonist in subarachnoid hemorrhage. Stroke 2007; 38: 3259-3265
57. Morrow DA, Scirica BM, Fox KAA, et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the thrombin-receptor antagonist in secondary prevention of atherothrombotic ischemic events (TRA 2°P)-TIMI 50 trial. Am Heart J 2009; 158: 335-41.e3
58. The TRA"CER Executive and Steering Committees. The thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA"CER) trial: study design and rationale. Am Heart J 2009; 158: 327-34.e4
59. Letienne R, Leparq-Panissie A, Calmettes Y, et al. Anti-thrombotic activity of F 16618, a new PAR1 antagonist evaluated in extracorporeal arterio-venous shunt in the rat. Biochem Pharmacol 2010; 79: 1616-1621
60. Planty B, Pujol C, Lamothe M, et al. Exploration of a new series of PAR1 antagonists. Bioorg Med Chem Lett 2010; 20